Correlations of GDF-15 with sST2, MMPs, and worsening functional capacity in idiopathic dilated cardiomyopathy: Can we gain new insights into the pathophysiology?

Journal of Circulating Biomarkers

Volumn 7, Issue , 2018, Pages

  Nair, Nandini ^a,b   Gongora, Enrique ^a,c  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c Memorial Cardiac and Vascular Institute   (United States)

Author keywords

GDF 15; LVEF; LVIDd; matrix metalloproteinases; sST2

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; GELATINASE A; GELATINASE B; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; INTERSTITIAL COLLAGENASE; STROMELYSIN;

ADULT; ARTICLE; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LEFT VENTRICULAR INTERNAL DIMENSION IN DIASTOLE; MALE; NEW YORK HEART ASSOCIATION CLASS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 85050677153     PISSN: None     EISSN: 18494544     Source Type: Journal    
DOI: 10.1177/1849454417751735     Document Type: Article

References (26)

1. Elliott P, Andersson B, Arbustini E. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases. Eur Heart J 2008; 29: 270–276
2. Mestroni L, Brun F, Spezzacatene A. Genetic causes of dilated cardiomyopathy. Prog Pediatr Cardiol 2014; 37: 13–81
3. Bootcov MR, Bauskin AR, Valenzuela SM. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA 1997; 94: 11514–11519
4. Jankovic-Tomasevic R, Pavlovic SU, Jevtovic-Stoimenov T. Prognostic utility of biomarker growth differentiation factor-15 in patients with acute decompensated heart failure. Acta Cardiol 2016; 71: 587–595
5. Boulogne M, Sadoune M, Launay JM. Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. Int J Cardiol 2017; 226: 53–59
6. George M, Jena A, Srivatsan V. GDF 15: a novel biomarker in the offing for heart failure. Curr Cardiol Rev 2016; 12: 37–46
7. Sinning C, Kempf T, Schwarzl M. Biomarkers for characterization of heart failure—distinction of heart failure with preserved and reduced ejection fraction. Int J Cardiol 2017; 227: 272–277
8. Aimo A, Vergaro G, Passino C. Prognostic value of soluble suppression of tumorigenicity-2 in chronic heart failure: a meta-analysis. JACC Heart Fail 2017; 5: 287–296
9. Xanthakis V, Larson MG, Wollert KC. Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening. J Am Heart Assoc 2013; 2: e000399
10. Takawale A, Sakamuri SS,, Kassiri Z. Extracellular matrix communication and turnover in cardiac physiology and pathology. Compr Physiol 2015; 5: 687–919
11. Müller AL, Dhalla NS. Role of various proteases in cardiac remodeling and progression of heart failure. Heart Fail Rev 2012; 17: 395–409
12. Müller AL, Freed D, Hryshko L. Implications of protease activation in cardiac dysfunction and development of genetic cardiomyopathy in hamsters. Can J Physiol Pharmacol 2012; 90: 995–1004
13. Santhanakrishnan R, Chong JP, Ng TP. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved versus reduced ejection fraction. Eur J Heart Fail 2012; 14: 1338–1347
14. Chan MM, Santhanakrishnan R, Chong JP. Growth differentiation factor 15 in heart failure with preserved versus reduced ejection fraction. Eur J Heart Fail 2016; 18: 81–88
15. Kramer DG, Trikalinos TA, Kent DM. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol 2010; 56: 392–406
16. Cotter G, Voors AA, Prescott MF. Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. Eur J Heart Fail 2015; 17: 1133–1143
17. Zeng X, Li L, Wen H. Growth-differentiation factor 15 as a predictor of mortality in patients with heart failure: a meta-analysis. J Cardiovasc Med (Hagerstown) 2017; 18: 53–59
18. Rouet-Benzineb P, Buhler JM, Dreyfus P. Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation. Eur J Heart Fail 1999; 1: 337–352
19. Heger J, Schiegnitz E, von Waldthausen D. Growth differentiation factor 15 acts anti-apoptotic and pro-hypertrophic in adult cardiomyocytes. J Cell Physiol 2010; 224: 120–126
20. Schwartzkopff B, Fassbach M, Pelzer B. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 2002; 4: 439–444
21. Picard F, Brehm M, Fassbach M. Increased cardiac mRNA expression of matrix metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) in DCM patients. Clin Res Cardiol 2006 5; 95: 261–269
22. Nakao K, Ogawa Y, Suga S. Molecular biology and biochemistry of the natriuretic peptide system. II: natriuretic peptide receptors. J Hypertens 1992; 10: 1111–1114
23. Sanada S, Hakuno D, Higgins LJ. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007; 117: 1538–1549
24. Iqbal N, Wentworth B, Choudhary R. Cardiac biomarkers: new tools for heart failure management. Cardiovasc Diagn Ther 2012; 2: 147–164
25. Kempf T, Eden M, Strelau J. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006; 98: 351–360
26. Lok SI, Winkens B, Goldschmeding R. Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur J Heart Fail 2012; 14: 1249–1256